Edwards Lifesciences gains as Europe drops antitrust investigation
Source: SeekingAlpha
2026-02-17 10:41:59 ET
More on Edwards Lifesciences
- Edwards Lifesciences Corporation (EW) Q4 2025 Earnings Call Transcript
- Edwards Lifesciences Corporation (EW) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- The Edwards Lifesciences Dilemma Persists: Strong Growth Potential, High Price
- Edwards Lifesciences outlines 8%–10% sales growth and $2.90–$3.05 EPS guidance for 2026 while advancing SAPIEN and TMTT platforms
- Edwards Lifesciences Non-GAAP EPS of $0.58 misses by $0.04, revenue of $1.57B beats by $30M
Read the full article on Seeking Alpha
For further details see:
Edwards Lifesciences gains as Europe drops antitrust investigation
Edwards Lifesciences Corporation
NASDAQ: EW
EW Trading
-0.65% G/L:
$84.905 Last:
1,676,803 Volume:
$86.11 Open:
EW Latest News
February 26, 2026 09:15:00 am
Edwards Lifesciences Advances Structural Heart Care Through Innovation and Purpose
February 20, 2026 12:22:22 am
ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing
February 19, 2026 07:05:00 am
Edwards Lifesciences to Present at the Barclays and Leerink Partners Global Healthcare Conferences
February 13, 2026 07:05:00 am
Edwards Lifesciences to Present at Citi's 2026 Unplugged Medtech and Life Sciences Access Day
EW Stock Data
$45,048,689,000
579,371,520
0.01%
691
N/A
Medical Equipment & Supplies
Healthcare
US
Irvine
